Additionally, pan‐cancer survival analysis showed that SLC12A5 could also functioned as a risk factor for OS in prostate adenocarcinoma (PRAD), liver hepatocellular carcinoma (LIHC) and kidney renal clear cell carcinoma (KIRC) (Figure S2D). This evidence concerns the gene SLC12A5 and prostate adenocarcinoma.